

"The Against the Gravity" N-COG Lift introduction and USER GUIDE

www.nfinders.com




Copyright © 2012 by N-Finders Co., Ltd. This document is solely for the use of client personnel. No part of it may be circulated, quoted, or reproduced for distribution outside the client organization without prior written approval from N-finders Co., Ltd. This document provides an outline of a presentation and is incomplete without the accompanying oral commentary and discussion.





.

+



- 100% biodegradable material which can be completely absorbed by the body and excreted through urine, exhaled as CO2 entirely after 6-8 months.
- Excellent flexibility, safe treatment without acute inflammation reaction.
- Used in surgical sutures and orthopedic


Minimal Invasive Lifting with Threads

- PDO thread lifting treatment tightens sagging skin tissue instantly
- The threads are inserted by needles, anchored, and pulled to lift the skin upwards and tightening the skin of the face

Instant lifting effect

Long term effect : Neocollagenesis , Neovascularization

• Procedure takes only 15 - 30 minutes





Clinical Importance

0

- Just local anesthesia: you can return to normal life immediately after the procedure.
- Minimal downtime
- No incisions or stitches are required
- No scars
- No secondary effects
- Suitable for everyone and applicable to the whole body

| | | | | | | | | | | | · · · | | | | | | | | | |
|---|---|-----|----|---|---|---|----|----|---|----|-------|----|---|------------------|---|----|---|----|----|--|
| | | | | | | 4 | ÷ | | | | 0 | 8 | | | | | | | | |
| | | | | | | 0 | ×. | | 0 | | | 2 | | | | ŝ. | | | | |
| | | | ×. | | | 0 | ×. | | | 0 | 0 | ×. | | | | ×. | | | | |
| | | | | | | 0 | ÷. | | | | 0 | ÷. | 0 | \mathbf{v}_{i} | | i. | 0 | | | |
| | | 6 | | | | 0 | ų. | | 8 | ÷. | 0 | i. | | 1 | | 0 | | ÷. | 0 | |
| | 0 | 0 | | 0 | | 0 | 0 | | | | | 0 | | ÷. | 0 | ũ. | 0 | | 0 | |
| | 0 | ÷., | | | | | 0 | | | | 0 | i. | | | | i. | | | ÷. | |
| | | | 0 | 0 | | | ï | ÷. | 0 | | 0 | i. | | 6 | | 0 | | | 0 | |
| | | | | | | | | | 0 | | | | | | | | | | | |
| , | | | | | | | | | | | | | 4 | | | 0 | | | | |
| | 0 | | | | | | | | | | | | 0 | | | 0 | | | | |
| | | | 0 | 0 | | | 0 | | | | | 0 | 0 | 0 | 0 | | | | 0 | |
| | 0 | | 0 | | 0 | 0 | | | | 0 | 0 | | | | | | | 0 | 0 | |
| | 0 | | | | | 0 | | | 0 | | 0 | | | | | | | | 0 | |
| | | | | | 0 | | | 0 | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | , | | |
| | | | 4 | | | | | | | | | | | | | i. | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |



Hand Made (molded thread x)

ISO 9001, ISO 13485, KGMP, CE, FSC, MFDS Certificate

Certificate of trademark registration/ ISO 9001:2015 / ISO 13485:2016 / EC Desig

n Examination certificate/

Certificate of service mark registration / Certificate of patent



.

FINDERS

EVIDENCE BASED MEDICINE


N-Cog lifting's effect has tested and proven by medical experiments, and clinical data and scienti fic papers (SCI reports) published on internationa l journals.



Various SCI reports

Derma Derma- Spring Study highlight Spring Bulge formation after inserting spring type PDO thread





(L) Insertion of 3-5 spring type PDO thread shows augmentation effect.

(R) Inside the tissue, the spring shape remains almost as same as it was before.

N-Cog Study highlight Bi-directional, Multi-directional Cogged Thread OG Bi-Directional PDO thread insertion, Multi-directional PDO thread insertion Skin is folding in accordance with inserted threads Folding is not observed



.



N-Finders has published several **PDO threads training books**, written by professors of human anatomy, plastic surgeons and dermatologist

A one of a kind complete and total guide series for perfect PDO threads lifting

.



.

N-Cog PDO Threads

MONO THREAD

COG THREAD

RE:MONO
SCREW
DERMA SPRING
DERMA SPRING EYE
SCAFFOLD


| N-COG |
|--------|
| SPIRAL |
| ROYAL |
| Ү-КО |
| N-FLIP |



Micro Punching Thread

D N-FIX


$(1, \dots, 1, \dots, \dots, 1, \dots,$











.



• RE: N-COG MULTI is a multiple bidirectional barbed PDO, specially designed to prevent

0 0

skin dimpling, protrusion and breakage of the thread once it is inserted inside the skin tissue.


| N-Cog | Multi | | 에-코그 [Newton Cog] |
|------------|----------|---------|-------------------|
| | | | |
| Needle | e (mm) | Threa | d(mm) |
| Gauge | Length | USP | Length |
| 23G | 60 | 3-0 | 100 |
| 23G | 90 | 3-0 | 130 |
| | Half-Cut | cannula | |
| 21G | 60 | 2-0 | 100 |
| 21G | 100 | 2-0 | 150 |

30 threads per box. (6 pouches with 5 units in individual sachet)

| | | | | | | | | ÷ | ~ | | | | | | | | | | |
|-----|----|---|----|----|----|----|---|-----|----|----|---|---|---|---|----|----|---|-----|--|
| | | | | a. | ÷ | | | | 0 | 8 | 0 | | | | | | | | |
| | | | | | 8 | | 0 | | 0 | 2 | 0 | 0 | | | 9 | | | | |
| | d. | | 0 | 0 | × | | | 0 | 0 | × | | | | 4 | ×. | | | | |
| | 0 | | | 0 | ×. | | | | 0 | 0 | 0 | 8 | | | ×. | 0 | | | |
| 0 | | 0 | 0 | 0 | 0 | | | 1 | 0 | Ű. | 0 | 1 | | | 0 | .0 | ÷ | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | | | 0 | .0 | 0 | 0 | | | 0 | 0 | 0 | | 0 | |
| ÷., | | | .0 | | 0 | | | | 0 | 0 | 0 | | | 0 | ÷. | | | | |
| | 0 | 0 | .0 | 0 | 0 | ÷. | 0 | | 0 | 0 | 0 | 0 | 0 | | 0 | | 0 | 0 | |
| | | | 0 | | | 1 | 0 | . 0 | | | | 0 | | | | | 0 | - 0 | |
| | | | | 2 | 1 | 1 | | | | 1 | 0 | | | | | 0 | 1 | | |
| 1 | | | | 0 | | | 1 | | 0 | | 0 | 1 | 1 | 2 | 0 | | 2 | 2 | |
| | 0 | 0 | | 0 | 0 | .0 | | | 0 | 0 | 0 | 0 | | 0 | 0 | | | 0 | |
| | 0 | 0 | 0 | 0 | | | | 0 | 0 | 0 | 0 | * | | | 2 | 0 | | 0 | |
| 2 | 0 | | | 0 | | | 0 | 0 | 0 | | 0 | 0 | | 0 | | | | 0 | |
| • | | | 0 | 0 | 8 | 0 | 0 | 0 | | 8 | 0 | 0 | 0 | 0 | 0 | | 0 | | |
| | 0 | 0 | 0 | 0 | 8 | 0 | | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | | 1 | | |
| | 1 | 0 | 0 | 0 | | 0 | | 0 | 0 | 0 | 0 | 0 | | 0 | | ~ | | | |

.

0



.



.

0 0 0

Draw a design line on the face or treatment part Considering patient's condition





.

9~11% lidocaine cream for 30~40 min Wipe the cream after







| | | | 1 | 0 | 0 | ÷. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 |
|---|---|---|---|---|---|----|---|---|---|---|---|---|---|---|----|---|---|---|
| - | | | | | | | 0 | | | | | 0 | | | | | 0 | 0 |
| (| | | | 2 | | 1 | | 1 | | | 0 | | 0 | 0 | 2 | 0 | | 0 |
| | | | ľ | 0 | | | 5 | 2 | 0 | | 0 | 2 | | 1 | 0 | | 1 | 0 |
| | | | 1 | 0 | 0 | 0 | 1 | 0 | | 0 | 8 | 0 | | 0 | 0 | | | 0 |
| | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 8 | 5 | 0 | | 0 |
| | | | 8 | 0 | 1 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 8 | 1 | | 0 |
| | | | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | | 0 | |
| | | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 8 | | 1 | |
| | 4 | | | 0 | | | | 0 | 0 | 0 | 0 | 0 | | 0 | i. | * | | |
| | | | | | | | | | | | | | | | | | | |


.

| | | | | 0 | . 0 | 0 | . 0 | 0 | 0 | 0 | 0 | .0 | 0 | 0.1 | .0 | .0 | . 9 | 0 | 10 |
|----------------------|-------------------------|----|----------|--------|-----|------|-----|-----|-----|------|-----|----------|---|-----|----|----|-----|----|----|
| | | | 0 | 0 | | | . 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | | .0 | 0 |
| | | 0 | 0 | 0 | 0 | 0 | 0 | | ũ. | | 0 | ÷. | 0 | 0 | | 0 | ×. | 0 | 0 |
| | | 0 | 0 | 0 | | 0 | ×. | 0 | 1 | 4 | 0 | .0 | 0 | 1 | ÷ | 1 | | 8 | ũ. |
| | | 1 | | | 1 | | | | 1 | 0 | | | | | | | | | 0 |
| | | | | | | 0 | 1 | 0 | 5 | | | | 0 | | | 2 | | 1 | 2 |
| | | 0 | | | | | 0 | | | | 0 | 0 | 0 | 0 | | | | 0 | 0 |
| ΤΠΕΑΤΜΕΝ | $\left \theta \right $ | Ρ | R | 0 | C | E | S | S | 0 | 0 | 0 | 1 | | | | | | | 1 |
| | | | .0 | 0 | | 0 | | | | 0 | 0 | 0 | | | | | | .0 | |
| ANESTHESI | Α | - | .0 | 0 | 0 | C-a | 3 | 2 | a r |) e | S | t | h | es | S- | а | | | 2 |
| | 0 | 0 | | | | | 0 | .0 | 0 | 0 | 0 | | 0 | 0 | | 0 | 0 | 0 | |
| Inject the anesthesi | 2.0 | | , tic | • n | | (on | j. | in | th | | ro | ः २ 1 | | ho | 0 | 9 | | | 0 |
| inject the anestnesi | d 2 | | luc | | ev | en | пy | 111 | u r | e c | ile | aı | 0 | De | | | | | |
| treated using a lon | g n | ee | dle | e. T | Thi | s is | s t | he | ba | asio | 2 | | 0 | | | | | | i. |
| anesthesia solution | 20 | di | i+ | vill | h | | 22 | do | 20 | | rd | ind | | | 0 | 0 | | 0 | ć. |
| | all | u | IL V | VIII | D | e i | IId | ue | a | .00 | nu | in iç | J | 0 | | 0 | 0 | | |
| user's preference. | | | | | | | ä | 0 | i. | 0 | 0 | | 0 | 0 | 0 | | | | |
| | | | | | | | | | | | | | | | | | | | |

Normal saline 50ml + Lidocaine HCL Hydrate 2%, 20ml (anesthetics) + sodium bicarbonate,(Na –bicarbonate) 5cc + Epinephrine 1ml



0 0



TREATMENT PROCESS

ANESTHESIA - Nerve block

* 30G needle with 10cc syringe with anesthetic solution (ex: lidocaine + Epi ,1% lidocaine 1~2cc injection)


.

* Entry point :: local anesthesia with dental lidocaine

1. Midface : Infraorbital nerve - the foramen lies along a line parallel to the midline that passes through the pupil and corner of the mouth.


- Area : lateral part of nose, lower eyelid, upper lip, cheek


2. Lower face : Mental nerve - Area : chin, lower lip



3. Upper face : supraorbital nerve - Area : supraorbital, supratrochlear, upper eyelid, forehead







.

POSSIBLE PRESCRIPTION

Prescriptions must be made according to the patient's circumstances at the judgment of the attending physician, and the responsibility for all prescriptions rests with the attending physician.

1. Aspirin : should not be terminated. However, bruising is more likely.

2. Patients at risk of Herpes labialis : advised to take prophylactic acyclovir tablets and should apply topical cream, especially if threads are to be inserted around the lips.


3. Arnica tablets : taken from about 5 days pre-treatment may be beneficial in reducing swelling after the treatment.

4. all blood 'thinning" supplements (Evening Primrose Oil, Vitamin C and Vitamin E and certain herbs) : Stop taking GENERAL

ENERAL AFTERCARE ADVICE

.

| | 0.00 | 0 0 | 6. 10 | 0 = 1 | 1.0 | -0 | 0 | |
|---|------|-----|-------|-------|-----|----|-----|-----|
| Some pain/discomfort after treatment can be expected, Ibuprofen can be taken if required | 0.1 | | | 0 1 | 1. | 1 | | |
| Do not have any other aesthetic procedures (such as toxins, fillers, peels etc.) for 7 days | | | | | | 1 | • • | |
| Avoid extreme temperatures, alcohol and anticoagulants for 7 days. Those taking Prescribed anticoagulants such as | | | | | | | | |
| aspirin/warfarin must continue to do so but must be aware that bruising is more likely | 0 | 0 0 | | × 1 | | | | 0 0 |
| Gently wash the treated area as required, but do not rub or massage for 2 weeks | | | | | | | | |
| It is important not to overstretch the treated area (i.e. open the mouth wide, avoid dental treatment about 2weeks if | | | | | | 5 | | |
| possible) | | | | | | | | |
| Do not have Radio-frequency, IPL, Laser or other heat treatments near the treated area for 2 weeks | | | | | 1 | 1 | | |
| Do not go to the sauna or do vigorous exercise on the day of the procedure | | 0 0 | | 0 0 | 0 | | • • | |
| Do not go to the sauna of do vigorous exercise on the day of the procedure | | | | • • | 1 | 0 | | 1 |
| | | | | | | | | |



0 0 0 0 0 0 0 0

Wedart

MID FACE 07-2

Jowl : N-Fix, N-Cog Multi / N-Cog Spiral

Entrance point :
Temporal hair line
End point : Extension line from mouth corner to ear lobe
Layer : SMAS layer in temple and cheek

N-Fix 21GX100 mm, 19GX100 mm N-Cog Multi or N-Cog Spiral 21GX100 mm

1

. . . .

.



.

.



6 1

.

.



.

· · · · · · · · · · · · · · · · · · ·



. 0 0 . 0 0 .

.

.



. 0 0 0 . 0 0 .

.

0 0

0 0 0



.

.

.

.



. .

0 0 0 Procedure 0 0 0

0 0 0 0 0

.

LOWER FACE 13-1

Marionette line : N-Cog Multi / N-Cog Spiral

Entrance point : • 1 cm anterior to the tragus **End point :** 1 cm medial to the marionette line Layer : SMAS layer

| \frown | | |
|----------|----|--|
| \Box | or | |

N-Cog Multi 21GX100 mm

N-Cog Spiral 21GX100 mm



. 0 0

.



. .

.

Procedures

.

LOWER FACE 17

Submandibular line : N-Cog Multi / N-Cog Spiral


Entrance point : • Lower border of the mastoid process End point : Vertical extension line from marionette line Layer : Subdermal or just above platysma muscle






N-Cog Multi 21GX100 mm

N-Cog Spiral 21GX100 mm






.

.

.



0 0 0

• Starting point the masteoid process (lower boarder)

.

0 0 0

full face (double chin)

.

0 0 0 0 0





0 0

.

.



. .

.

- Stimulates patient's intrinsic healing process in order to re-shape the nose.
- Re-Shape your nose in less than 15 minutes and without surgery. Lift the tip of the nose, alignment of the nasal dorsum, and reduction of the nasal wings


.

N-Cog Y-KO



| Half-Cut ca | nnula (mm) | Thread | d(mm) |
|-------------|------------|--------|--------|
| Gauge | Length | USP | Length |
| 19G | 40 | 0 | 40 |
| 21G | 60 | 2-0 | 90 |

30 threads per box. (6 pouches with 5 units in individual sachet)



.

MID FACE 12-1

Nasal dorsum augmentation, Nasal tip elevation and Nostril reduction : Y-KO


Entrance point : ● 0.5 cm below the tip of the nose End point : Nasal dorsum_Glabella, Columella_Anterior nasal spine Layer : Nasal dorsum_Supraperiosteal layer,

Columella_Intercrural space




Y-Ko 21GX60 mm **Y-Ko** 19GX40 mm

When performing a nasal dorsum augmentation, insert Y-KO thread through the supraperiosteal layer from 0.5 cm below the nasal tip. Withdraw the cannula once the tip of cannula touches the bone of the glabellar area. For nasal tip elevation and nostril reduction, insert Y-KO thread through the intercrural space of columella from 0.5 cm below the tip of he nose. Withdraw the cannula once the cannula tip touches the anterior nasal spine.





.



- 1. Nasal ridge insertion : Insert N-Cog Y-Ko 21G 60mm needle between 2 Alar cartilage, thought Lateral cartilage to Nasal bone. When you follow the bone, you will meet resistance force before Nasal bone. Upraise the needle for smooth insertion.
- 2. Nasal tip insertion : Insert N-Cog Y-Ko 19G 40mm Use the same insertion point with Nasal ridge insertion, Insert vertically thought the cloume of the nose till you meet the bone.

.

.



. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 .

.

0 0 0 0 0

.

.



. 0 0 0 0 0 0 0.0 0 0 0 0 0 . 0 0 0 0 /

.

. Procedures : Y-Ko

. .

> .





| | | | | | | | | | | | | | | T | | |
|---------|---|---|----|----|---|--------|---|----|---|---|---|---|----|---|---|-----|
| | | | | | | \sim | - | | | | | | | | | |
| | | | 0 | 0 | | | 0 | 8 | 0 | | | | | | | |
| | | | | .0 | | | | | | 0 | | | 9 | | | |
| | | | ×. | 0 | 0 | | 0 | × | | | | 0 | ×. | | | |
| | | | 2 | | | | 0 | 4 | 0 | 0 | | | | 0 | | |
| | | 1 | 0 | 0 | | | 0 | ÷. | 0 | | | | .0 | | 6 | |
| | | | 0 | | | | 0 | 0 | | 0 | | 0 | 0 | 0 | | |
| | | | 0 | | | | 0 | ũ. | 0 | | | 0 | i. | | | ŝ |
| | | | i. | ÷. | 0 | | 0 | ũ | 0 | 0 | | | 0 | | 0 | .0 |
| | | | | | • | | | | | | | | | | | - 1 |
| | | | | | | | | | 0 | | | | 0 | 0 | | |
| | | | | | 5 | | 0 | | 0 | ÷ | | | 0 | 0 | ÷ | |
| | | | 0 | 0 | ÷ | | | 0 | 0 | 0 | | 0 | 0 | | | 0 |
| | | | | 0 | 0 | | 0 | | 0 | | 0 | | | 0 | | 0 |
| | | | | | | | 0 | | | | | | | | | 0 |
| | | | 8 | 0 | | | 0 | ÷ | 0 | 0 | | 0 | ų. | | 0 | |
| (0) | 0 | 0 | | | | | | | | • | | 0 | | | | |

. .

Procedures : Derma Spring





1 1 1 1 1

1 0 0 0 0



.

| | | | | | | 1 | | | | | | | | | | |
|---|---|---|----|----|---|-----|----|----|---|---|----|---|----|----|---|---|
| 1 | | | | | | | 0 | 8 | | | | | | | | |
| | | | | | 8 | | 0 | 2 | | 0 | 0 | | 9 | | | |
| - | 5 | | | | | 0 | 0 | ×. | | | 0 | | i. | | | |
| | 1 | | | | | | 0 | 0 | 0 | 8 | .0 | 0 | | 0 | | |
| | | | | | 8 | | 0 | Ű. | 0 | 0 | | 0 | .0 | | 6 | 0 |
| | | | | | | | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | | 0 |
| | | | | | 9 | .0 | 0 | ũ | 0 | | .0 | 0 | Ű. | 0 | 0 | |
| | | | | | 0 | | 0 | 0 | 0 | 0 | 0 | | 0 | .0 | 0 | 0 |
| | | | | | 0 | . 0 | | | | 0 | 0 | | | | 0 | |
| | | | | | | | | 2 | 0 | | 0 | | 0 | .0 | 2 | |
| | | | | | 5 | | 0 | | 0 | 1 | | | 0 | | 1 | |
| | | | | | | | 0 | 0 | 0 | 0 | | 0 | 0 | | | 0 |
| | | | | | 0 | 0 | 0 | 0 | 0 | * | 0 | 0 | 8 | 0 | | 0 |
| | | | | | 0 | | 0 | | 0 | 0 | 0 | 0 | | | | 0 |
| | | | | | 0 | | 0 | 8 | 0 | 0 | 0 | | 0 | .0 | 0 | |
| | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | | 1 | |
| | | 0 | | | | 0 | 0 | | 0 | | | 0 | | * | | |
| | | 0 | 10 | .0 | | .0 | .0 | | 0 | | 0 | 0 | | | | |




.

Comparison: type of a thread

.

| 0 0 0 0 | | | |
|------------------|---|--|-------|
| | Contour thread | Non-Contour thread | |
| Material | Polypropylene, PDO, PLLA | PDO, PLLA, PCL | |
| Example | Aptos, Silhouette | N-Cog Lift | |
| Action Mechanism | Artificial Lifting Lift up the drooped tissue | Natural Lifting Fix and prevent the drooping of tissue Using thread tissue interaction | |
| Type of thread | Bidirectional cog - cutting, molding, cone | Multiple bidirectional cog - cutting, molding, punching Braided, Weaving Monofilament Spring shape | |
| Complications | Asymmetricity Migration and protrusion Early drooping | Edema Purpura | |
| | | | • • • |

Comparison: Material of a the




tal studies on the ring opening polymerization of p-dioxanone using an Al(OiPr)3

monosaccharide initiator system

* Aleksandra et al. / Polish Journal of Chemical Technology, 19(201)

β. Biodegradation of poly(ε-caprolactone) in natural water environment

Comparison: why PDO?



* G. Sulamanidze et al. / Journal of Cosmetic Dermatology 17(2018) 731–735, Pathomorphological criteria of use efficiency of resorbable and permanent implant in aesthetic medicine and cosmetic dermatology.

FINDERS

.

Comparison: why PDO?

Physical lifting effects

- Long Duration means good for lifting?
- PDO< PLA<PCC<PP
- Long duration does not guarantee the best result.
- After some time passed from thread insertion, physical lifting effect will gone after 6~12 months for all type of the thread.
- PP is non-absorbable thread, looks have a good physical effect from a start, but it will droped down in the same time of PDO thread.
- Stay long and make long inflammantory response might interrupt general function of the subject tissues and might cause granuloma with harsh foreign body reactions.

JAMA Facial Plastic Surgery | Original Investigation

Research

Assessment of Scaffolding Properties for Chondrogenic Differentiation of Adipose-Derived Mesenchymal Stem Cells in Nasal Reconstruction

Serban San-Marina, MD, PhD; Ayushman Sharma, MD; Stephen G. Voss, MS; Jeffrey R. Janus, MD; Grant S. Hamilton III, MD

+ Supplemental content

IMPORTANCE Nasal reconstruction in patients who are missing a significant amount of structural nasal support remains a difficult challenge. One challenge is the deficiency of cartilage left within the nose as a consequence of rhinectomy or a midline destructive disease. Historically, the standard donor source for large quantities of native cartilage has been costal cartilage.

OBJECTIVE To enable the development of protocols for new mesenchymal stem cell technologies as alternative procedures with reduced donor site morbidity, risk of infection and extrusion.

DESIGN_SETTING_AND MATERIALS. We examined 6 popular scaffold materials in current practice in terms of their biodegradability in tissue culture, effect on adipose-derived mesenchymal stem cell growth, and chondrogenic fate commitment. Various biomaterials of matching size, porosity, and fiber alignment were synthesized by electrospinning and overlaid with rabbit adipose-derived mesenchymal cells in media supplemented or not with chondrogenic factors. Experiments were performed in vitro using as end points biomarkers for cell growth and chondrogenic differentiation. Polydioxanone (PDD), poly-3-hydroxybutyrate-co-3-hydroxyvalerate (PHBV), PHBV-polycaprolactone, polyl-1-actide-co-caprolactone), polyllactic-co-gylocilc acid), and polystyrene scaffolds of 60% to 70% porosity and random fiber alignment were coated with poly(L)-lysine/laminin to promote cell adhesion and incubated for 28 days with 2.5 to 3.5 × 10° rabbit adipose mesenchymal cells.

MAIN OUTCOMES AND MEASURES Cell growth was measured by fluorometric DNA quantitation and chondrogenic differentiation of stem cells by spectrophotometric sulfated glycosaminoglycan (sGAG) assay. Microscopic visualization of cell growth and matrix deposition on formalin-fixed, parafin-embedded tissue sections was performed, respectively, with nuclear fast red and Alcian blue.

RESULTS OF 6 scaffold materials tested using rabbit apidose mesenchymal cells, uncoated scaffolds promoted limited cell adhesion but coating with poly(1)-lysine/laminin enabled efficient cell saturation of scaffold surfaces, ables with limited involvement of scaffold interiors. Similar growth rates were observed under these conditions, based on DNA content analysis. However, PDO and PHBV/PCL scaffolds supported chondrogenic fate commitment better than other materials, based on soluble ScAG analysis and microscopic observation of chondrogenic matrix deposition. The mean (SD) sGAG scaffold values expressed as fold increase over control were PDO, 2.26 (0.88), PHBV/PCL, 2.09 (0.83), PLCL, 1.36 (0.39), PLGA, 1.34 (0.7), PHBV.107 (0.31), and PS, 0.38 (0.14).

CONCLUSIONS AND RELEVANCE These results establish materials, reagents, and protocols for tissue engineering for nasal reconstruction using single-layer, chondrogenically differentiated, adipose-derived mesenchymal stem cells. Stackable, scaffold-supported, multisheet bioengineered tissue may be generated using these protocols.

LEVEL OF EVIDENCE NA.

JAMA Factal Plast Surg. doi:10.1001/jamafacial.2016.1200 Published online October 13, 2016. Author Affiliations: Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota. Corresponding Author: Serban San-Marina, MD, PhD, Department of Otolaryngology, Mayo Clinic, 200 Its St SW, Rochester, IM 55902 (cammarina serbang)mayo.edu).

E1


Copyright 2018 American Medical Association. All rights reserved

.

.

ownloaded From: http://jamanetwork.com/ by Soo Choi on 11/28/2016







4 | DISCUSSION

Currently, fillers for facial volume augmentation are largely divided into two types, hyaluronic acid (HA) and biostimulatory fillers

Poly-L-lactic acid has biostimulatory effects through macrophages, (myo-)fibroblasts, and collagen that orchestrate capsule formation. The reaction starts with subclinical inflammation that continues to microparticle encapsulation and then to collagen production by the host.¹⁰ PLLA itself degrades into carbon dioxide and water, and the surrounding collagen production continues even after

.

. .

0 0

0.0

0 0

10.1

. 0

0 .


0 0 0

6 6 6

.

Comparison: why PDO?

- Chemical feature Safty
- PP < PCL > PLA < PDO
- PLA leaves lactic acid and hydroxy acid as a intermediate product during biodegradation.
- This might cause hardship to get the correct body test result such as CPR test of subject during thread remains.
- Meanwhile, PDO will completely absorbed and excreted mainly in urine.



.

Conclusion : why PDO?

PDO is the most safe and effect material for lifting.



N-SCAFFOLD BRAID

FINDERS

